CwpV Antibody Diagnostic Marker for C. difficile Ribotype 027 Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating Clostridium difficile (C. difficile) strains, particularly the hypervirulent ribotype 027, are cumbersome, expensive, and non-specific, leading to challenges in treatment decision-making and high relapse rates due to the disturbance of gut flora by broad-spectrum antibiotics.
Innovation Solution
Utilization of ribotype-specific Cell Wall Protein V (CwpV) as a diagnostic marker in immunoassays, specifically using anti-CwpV antibodies to identify C. difficile ribotype 027 through ELISA and QUIK CHEK® tests, which are rapid and cost-effective, facilitating accurate differentiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional typing methods (PFGE, PCR ribotyping) are used to differentiate C. difficile strains, then measurement precision is improved, but device complexity and loss of time increase
Solution Approach 1:
The patent extracts the specific diagnostic function from complex molecular typing methods by focusing on a single strain-specific antigen (the 18-base pair deletion region in tcdC gene). Instead of performing complete PCR ribotyping or PFGE, the invention uses ELISA to detect only the critical differentiating feature, thereby simplifying the testing procedure while maintaining strain differentiation accuracy
Solution Approach 2:
The patent changes the detection parameter from molecular methods (DNA amplification and electrophoresis) to immunological detection (antigen-antibody binding). By using ELISA to detect strain-specific antigens rather than performing complex molecular typing, the invention reduces device complexity and testing time while preserving the ability to accurately differentiate strains
2Productivity
If broad-spectrum antibiotics are used to treat CDI, then productivity is improved by treating multiple strains, but object-generated harmful factors increase due to gut flora disturbance and high relapse rates
Solution Approach 1:
The patent implements feedback by using strain-specific diagnostic testing (ELISA detecting ribotype 027 antigens) to guide treatment decisions. The test results provide information about the specific strain present, allowing clinicians to adjust treatment strategies accordingly - using targeted antibiotics for ribotype 027 and appropriate alternatives for other strains, thereby reducing relapse rates while maintaining effective treatment coverage
Solution Approach 2:
The patent applies local quality by differentiating treatment approaches based on specific strain characteristics. Instead of uniform broad-spectrum antibiotic treatment, the invention enables tailored therapy where ribotype 027 infections receive specific antibiotic regimens (such as fidaxomicin or targeted vancomycin courses) while other strains receive appropriately matched treatments, optimizing outcomes and reducing unnecessary gut flora disturbance
3Measurement precision
If PCR ribotyping is used for strain identification, then measurement precision is improved, but loss of time and use of energy increase
Solution Approach 1:
The patent extracts only the essential diagnostic information needed for strain identification from the complex PCR ribotyping process. By using ELISA to detect strain-specific antigens (particularly the 18-base pair deletion region in ribotype 027), the invention obtains the critical diagnostic result without performing complete molecular typing, thereby reducing testing duration while maintaining identification accuracy
Solution Approach 2:
The patent substitutes mechanical/molecular methods (PCR amplification and gel electrophoresis) with immunological detection (ELISA). By replacing the complex molecular biology workflow with antigen-antibody binding assays, the invention reduces both testing time and energy consumption while preserving the ability to accurately identify strains
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-CwpV ELISA and QUIK CHEK® tests demonstrate high sensitivity and specificity in identifying ribotype 027 strains, reducing treatment uncertainties and potentially lowering relapse rates by enabling targeted antibiotic use.
Implementation Method 1
anti-CwpV antibodies are used in immunoassays for highly sensitive identification of C. difficile strain 027
Data Source
AI summary
Accurate and rapid differentiation of the outbreak strain ribotype 027 from other possible Clostridium difficile (C. difficile) strains, using stool samples, facilitates decision making for treatment options. Cell wall protein V (CwpV) contains a cell wall binding domain conserved among C. difficile strains and a variable domain which is antigenically different among C. difficile strains. In embodiments, antibodies against the 027-specific region in CwpV are used in diagnostic tests to detect ribotype 027 in culture or fecal samples.